Search Results
14 Results Found for “Micra AV”
As 2025 draws to a close, we’re celebrating another remarkable year of growth, collaboration and innovation at touchCARDIO. From thought-provoking expert interviews and peer-reviewed research to dynamic conference coverage and an expanding portfolio of medical education, this year has been defined by meaningful conversations and impactful learning. We’ve had the privilege of engaging with leading clinicians, researchers and partner societies across the globe - bringing together diverse voices to support the cardiology community with timely, accessible and authoritative content. As we reflect on the past 12 months, we’re proud to highlight the moments, milestones and stories that shaped our year.
Welcome to this issue of Heart International. As ever, we aim to provide our readers with the latest developments, insights, and evidence-based discussions in cardiovascular care. This edition is particularly poignant, as we begin with a heartfelt tribute to an ...
The first-in-human implantation of a leadless pacing system occurred already more than 10 years ago.1 The first-generation ventricular leadless pacemaker could provide only asynchronous ventricular pacing (ventricular, ventricular, inhibited [VVI], or ventricular, ventricular, inhibited, rate response [VVIR]), limiting its indications to ...
The OptiVALL study aimed to assess the atrioventricular synchronous pacing capabilities of the Micra AV device, and to describe what programming changes are needed. In this touchCARDIO interview, we speak with Dr Sem Briongos Figuero (Hospital Infanta Leonor, Madrid, Spain) ...
The MARVEL 2 trial studied atrioventricular synchronous pacing in patients with a Micra leadless ventricular pacemaker. In this touchCARDIO interview, we speak with Dr Sem Briongos Figuero (Hospital Infanta Leonor, Madrid, Spain) to discuss the trials studying atrioventricular synchrony and their ...
Case: A 58-year-old male with dual chamber pacemaker implanted 14 years previously for sinus node disease presented with red papular rash and burning pain over pacemaker site. He was initially treated with antibiotics for presumed device relate infection. Normal white cell ...
Case report A 50-year-old man with a history of myocardial infarction (MI) in 2006 and arterial hypertension presented with episodes of paroxysmal atrio-ventricular block (AVB). He was also affected by severe obesity (353 kg) with a body mass index (BMI) of 121 kg/...
Introduction and methods: Cardiac implantable electronic device (CIED) procedures are associated with complications. Our centre has incorporated multiple measures to minimize implant complications, but the rates of complications in contemporary clinical practice are not well described. We avoid heparin bridging, ...
Introduction: The Micra post-approval registry (PAR) and Micra Acute Performance regional cohort (MAP; conducted in Europe, Middle East, and Africa [EMEA]) are ongoing prospective registries designed to evaluate safety and performance of the Micra transcatheter pacing system in the post-market ...
Background: Leadless pacemakers were developed as an alternative pacing modality in patients who cannot undergo transvenous pacing. Early data suggested a good safety and efficacy profile, however real-world data is limited. Purpose: To report our single tertiary centre experience in ...
Introduction: The Micra TPS, a leadless single-chamber ventricular pacemaker, is increasingly preferred over the transvenous system. Its significantly smaller profile and fewer reported adverse effects, without compromising the pacing efficacy, makes it an innovative pacing device. We report the first ...
Introduction: Day case device procedures are now standard practice however there still appears to be some uncertainty and no clear guidance in the post implant device check policies. The majority of complications with devices occur in-hospital or during the first 6 ...
Background: Leadless pacemaker therapy is associated with a significant reduction in complication rate as compared with conventional transvenous single chamber pacemaker. However, vascular access complication is around 1.2% due to large delivery femoral sheath (27Fr). We examined the importance of real-time ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
